vs

Side-by-side financial comparison of FIRST US BANCSHARES, INC. (FUSB) and Xilio Therapeutics, Inc. (XLO). Click either name above to swap in a different company.

Xilio Therapeutics, Inc. is the larger business by last-quarter revenue ($13.7M vs $10.4M, roughly 1.3× FIRST US BANCSHARES, INC.). Xilio Therapeutics, Inc. runs the higher net margin — 75.7% vs 20.4%, a 55.3% gap on every dollar of revenue. FIRST US BANCSHARES, INC. produced more free cash flow last quarter ($9.1M vs $-2.1M).

First Citizens Bancshares, Inc. is a bank holding company based in Raleigh, North Carolina and one of the largest banks in the United States. Its primary subsidiary is First Citizens Bank, which operates over 500 branches in 23 states. A second subsidiary is Silicon Valley Bank, which operates 39 offices in 15 states.

Xilio Therapeutics is a clinical-stage biotechnology company dedicated to developing novel tumor-selective immunotherapies for cancer treatment. Its product pipeline features candidates engineered to trigger anti-tumor immune responses specifically inside tumor microenvironments, reducing systemic toxicities, and it primarily targets oncology patient populations in North America and other global markets.

FUSB vs XLO — Head-to-Head

Bigger by revenue
XLO
XLO
1.3× larger
XLO
$13.7M
$10.4M
FUSB
Higher net margin
XLO
XLO
55.3% more per $
XLO
75.7%
20.4%
FUSB
More free cash flow
FUSB
FUSB
$11.2M more FCF
FUSB
$9.1M
$-2.1M
XLO

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
FUSB
FUSB
XLO
XLO
Revenue
$10.4M
$13.7M
Net Profit
$2.1M
$10.4M
Gross Margin
Operating Margin
28.1%
-86.5%
Net Margin
20.4%
75.7%
Revenue YoY
7.1%
Net Profit YoY
24.2%
179.1%
EPS (diluted)
$0.36
$-3.74

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FUSB
FUSB
XLO
XLO
Q4 25
$10.4M
$13.7M
Q3 25
$10.5M
$19.1M
Q2 25
$10.3M
$8.1M
Q1 25
$9.8M
$2.9M
Q4 24
$9.7M
Q3 24
$10.1M
Q2 24
$10.0M
Q1 24
$9.9M
Net Profit
FUSB
FUSB
XLO
XLO
Q4 25
$2.1M
$10.4M
Q3 25
$1.9M
$-16.3M
Q2 25
$155.0K
$-15.8M
Q1 25
$1.8M
$-13.3M
Q4 24
$1.7M
Q3 24
$2.2M
Q2 24
$2.1M
Q1 24
$2.1M
Operating Margin
FUSB
FUSB
XLO
XLO
Q4 25
28.1%
-86.5%
Q3 25
23.9%
-10.1%
Q2 25
1.6%
-177.7%
Q1 25
23.8%
-472.7%
Q4 24
23.8%
Q3 24
29.2%
Q2 24
27.4%
Q1 24
27.8%
Net Margin
FUSB
FUSB
XLO
XLO
Q4 25
20.4%
75.7%
Q3 25
18.4%
-85.4%
Q2 25
1.5%
-196.0%
Q1 25
18.1%
-452.7%
Q4 24
17.6%
Q3 24
22.0%
Q2 24
21.2%
Q1 24
21.3%
EPS (diluted)
FUSB
FUSB
XLO
XLO
Q4 25
$0.36
$-3.74
Q3 25
$0.32
$-0.11
Q2 25
$0.03
$-0.16
Q1 25
$0.29
$-0.18
Q4 24
$0.29
Q3 24
$0.36
Q2 24
$0.34
Q1 24
$0.34

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FUSB
FUSB
XLO
XLO
Cash + ST InvestmentsLiquidity on hand
$73.5M
$137.5M
Total DebtLower is stronger
$10.9M
Stockholders' EquityBook value
$105.6M
$35.3M
Total Assets
$1.2B
$154.7M
Debt / EquityLower = less leverage
0.10×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FUSB
FUSB
XLO
XLO
Q4 25
$73.5M
$137.5M
Q3 25
$54.7M
$103.8M
Q2 25
$54.0M
$121.6M
Q1 25
$56.0M
$89.1M
Q4 24
$47.2M
Q3 24
$82.3M
Q2 24
$58.2M
Q1 24
$60.2M
Total Debt
FUSB
FUSB
XLO
XLO
Q4 25
$10.9M
Q3 25
$10.9M
Q2 25
$10.9M
Q1 25
$10.9M
Q4 24
$10.9M
Q3 24
$10.9M
Q2 24
$10.8M
Q1 24
$10.8M
Stockholders' Equity
FUSB
FUSB
XLO
XLO
Q4 25
$105.6M
$35.3M
Q3 25
$104.2M
$-8.1M
Q2 25
$101.9M
$7.1M
Q1 25
$101.2M
$10.7M
Q4 24
$98.6M
Q3 24
$98.5M
Q2 24
$93.8M
Q1 24
$92.3M
Total Assets
FUSB
FUSB
XLO
XLO
Q4 25
$1.2B
$154.7M
Q3 25
$1.1B
$133.7M
Q2 25
$1.1B
$133.8M
Q1 25
$1.1B
$103.7M
Q4 24
$1.1B
Q3 24
$1.1B
Q2 24
$1.1B
Q1 24
$1.1B
Debt / Equity
FUSB
FUSB
XLO
XLO
Q4 25
0.10×
Q3 25
0.10×
Q2 25
0.11×
Q1 25
0.11×
Q4 24
0.11×
Q3 24
0.11×
Q2 24
0.12×
Q1 24
0.12×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FUSB
FUSB
XLO
XLO
Operating Cash FlowLast quarter
$12.3M
$-2.0M
Free Cash FlowOCF − Capex
$9.1M
$-2.1M
FCF MarginFCF / Revenue
87.2%
-15.3%
Capex IntensityCapex / Revenue
31.1%
0.7%
Cash ConversionOCF / Net Profit
5.79×
-0.19×
TTM Free Cash FlowTrailing 4 quarters
$16.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FUSB
FUSB
XLO
XLO
Q4 25
$12.3M
$-2.0M
Q3 25
$4.2M
$-17.5M
Q2 25
$3.9M
$-14.5M
Q1 25
$1.8M
$29.0M
Q4 24
$7.8M
Q3 24
$1.9M
Q2 24
$2.5M
Q1 24
$825.0K
Free Cash Flow
FUSB
FUSB
XLO
XLO
Q4 25
$9.1M
$-2.1M
Q3 25
$3.6M
Q2 25
$1.6M
$-14.9M
Q1 25
$1.7M
$29.0M
Q4 24
$5.7M
Q3 24
$1.3M
Q2 24
$2.3M
Q1 24
$-142.0K
FCF Margin
FUSB
FUSB
XLO
XLO
Q4 25
87.2%
-15.3%
Q3 25
34.2%
Q2 25
16.0%
-184.0%
Q1 25
17.2%
988.3%
Q4 24
58.2%
Q3 24
12.7%
Q2 24
23.5%
Q1 24
-1.4%
Capex Intensity
FUSB
FUSB
XLO
XLO
Q4 25
31.1%
0.7%
Q3 25
5.9%
0.0%
Q2 25
21.8%
5.0%
Q1 25
0.7%
0.8%
Q4 24
21.6%
Q3 24
6.6%
Q2 24
2.0%
Q1 24
9.8%
Cash Conversion
FUSB
FUSB
XLO
XLO
Q4 25
5.79×
-0.19×
Q3 25
2.18×
Q2 25
25.16×
Q1 25
0.99×
Q4 24
4.53×
Q3 24
0.87×
Q2 24
1.20×
Q1 24
0.39×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons